Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme

Volumetric and MGMT parameters in glioblastoma patients: Survival analysis

(2012) Georgios Iliadis et al.   BMC CANCER

IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom

(2012) Florian Stockhammer et al.   SEIZURE-EUROPEAN JOURNAL OF EPILEPSY

Efficacy and Safety of Levetiracetam in Patients With Glioma

(2010) Anna Rosati et al.   ARCHIVES OF NEUROLOGY

Cancer Metabolism: Is Glutamine Sweeter than Glucose?

(2010) Weiqin Lu et al.   CANCER CELL

Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation

(2010) Jian-Bin Wang et al.   CANCER CELL

Glutamine Synthetase Immunostaining Correlates with Pathologic Features of Hepatocellular Carcinoma and Better Survival after Radiofrequency Thermal Ablation

(2010) B. Dal Bello et al.   CLINICAL CANCER RESEARCH

Selective induction of astrocytic gliosis generates deficits in neuronal inhibition

(2010) Pavel I Ortinski et al.   NATURE NEUROSCIENCE

Glutamine addiction: a new therapeutic target in cancer

(2010) David R. Wise et al.   TRENDS IN BIOCHEMICAL SCIENCES

Tumor-associated epilepsy and glioma: Are there common genetic pathways?

(2009) Shala Ghaderi Berntsson et al.   ACTA ONCOLOGICA

Epilepsy in glioblastoma multiforme: correlation with glutamine synthetase levels

(2009) Anna Rosati et al.   JOURNAL OF NEURO-ONCOLOGY

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

(2009) Michael Weller et al.   Nature Reviews Neurology

Independent association of extent of resection with survival in patients with malignant brain astrocytoma

(2008) Matthew J. McGirt et al.   JOURNAL OF NEUROSURGERY

Neuro-oncology: clinical and molecular predictive factors

(2008) Charles J Vecht   LANCET NEUROLOGY

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY